Novo Nordisk’s sales increased by 12% in Danish kroner and
Bagsværd, 5 November, 2025 – Financial report for the period 1 January 2025 to 30 September 2025  …
Novo Nordisk and Omeros announce asset purchase and license
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease…
Novo Nordisk to acquire Akero Therapeutics and its
Acquisition adds potential first- and best-in-class asset, enhancing Novo Nordisk’s portfolio for treatment of MASH, one of the…